What Is Retatrutide? The Triple Agonist Peptide Explained

Weight loss science is moving fast. While medications like Ozempic and Mounjaro have reshaped how clinicians approach obesity, a new compound is showing results that could surpass them both. Retatrutide is a weekly injectable peptide currently in advanced clinical development, designed to work on three separate hormonal pathways rather than one or two.

This article unpacks what retatrutide is, how it works at the receptor level, what the clinical trial data shows, and what patients and researchers need to know before it reaches pharmacy shelves.

Quick Overview and Intended Uses

Retatrutide is a long-acting synthetic peptide administered as a weekly subcutaneous injection. It is classified as a triple agonist, simultaneously targeting three key metabolic receptors: GLP-1, GIP, and the glucagon receptor.

It is being developed primarily by Eli Lilly for three clinical targets:

• Obesity: significant body weight reduction in individuals with a BMI qualifying for pharmacological intervention
• Type 2 diabetes: improved blood sugar control and insulin sensitivity
• Fatty liver disease (NAFLD): reduction of liver fat content in people with metabolic-related liver conditions

Retatrutide is currently in Phase 3 clinical trials and is not yet commercially available.

How Retatrutide Works

Most incretin-based medications target a single receptor. Semaglutide targets only GLP-1. Tirzepatide targets GLP-1 and GIP. Retatrutide goes further by activating all three key metabolic receptors simultaneously, which is why it is classified as a triple agonist, sometimes referred to as a “triple G” peptide.

GLP-1 Receptor Effects

GLP-1 mimics a gut hormone naturally released after eating. When retatrutide activates this receptor, it slows gastric emptying, meaning food stays in the stomach longer and satiety signals are extended. The result is a meaningful reduction in hunger and overall calorie intake without the patient needing to consciously restrict eating.

GIP Receptor Effects

GIP activation improves insulin sensitivity, helping the body manage blood sugar levels more effectively, which is particularly relevant for type 2 diabetes management. GIP also acts on receptors to improve metabolic function and mitigate nausea, giving retatrutide a potentially more tolerable side effect profile than GLP-1 monotherapy.

Glucagon Receptor Effects

By engaging the glucagon receptor, the drug increases energy expenditure and promotes fat oxidation, the metabolic process of breaking down stored fat for fuel. Glucagon receptor agonism is not present in semaglutide or tirzepatide, and it may explain why retatrutide’s early weight loss figures exceed both. As peptide therapies continue to reshape modern medicine, triple receptor strategies like this represent the leading edge of metabolic research.

Clinical Trials and Evidence

Retatrutide has progressed through Phase 1 and Phase 2 clinical programmes, with Phase 3 trials currently underway. In the Phase 2 trial, participants using the highest dose lost an average of 17.5% of body weight in 24 weeks. Those who continued for 48 weeks saw an average weight reduction of 24.2%, figures that exceeded outcomes typically reported with GLP-1-only medications at comparable timepoints.

The Phase 3 clinical trials are designed to evaluate effectiveness and safety across a broader population, including individuals with type 2 diabetes, cardiovascular risk factors, and NAFLD.

Trial Safety Signals

The safety profile of retatrutide is similar to other medications in its class. The most commonly reported side effects were gastrointestinal and typically mild to moderate in severity. Importantly:

• No cases of severe hypoglycemia were reported
• No fatalities were reported during Phase 2 trials
• Most side effects resolved without discontinuing the medication

Average Weight Loss Seen in Trials

Retatrutide has shown a weight reduction of 24% after 48 weeks, comparable to Mounjaro’s ~22.5% over 72 weeks, but achieved in a shorter time frame. At the six-month mark, participants had already lost an average of 17.5% of their starting body weight, a figure greater than what is typically observed with GLP-1 medications like Ozempic and Wegovy at similar intervals.

Medication	Receptor Targets	Avg. Weight Loss	Trial Duration
Retatrutide	GLP-1 + GIP + GCG	~24.2%	48 weeks
Tirzepatide (Mounjaro)	GLP-1 + GIP	~22.5%	72 weeks
Semaglutide (Wegovy)	GLP-1 only	~15%	68 weeks

Retatrutide and Fatty Liver Disease

Early studies indicate that retatrutide may help reduce liver fat in individuals with obesity, potentially preventing the progression of non-alcoholic fatty liver disease (NAFLD). NAFLD affects a large proportion of people with obesity and type 2 diabetes, and currently has limited pharmacological treatment options.

The glucagon receptor component is believed to play a central role, as glucagon signalling actively promotes fat metabolism in the liver. If Phase 3 data confirms the liver fat reductions seen in earlier trials, retatrutide could offer a single intervention that addresses weight, blood sugar, and liver health simultaneously.

Side Effects of Retatrutide

The side effects of retatrutide are consistent with other medications in its class. Gastrointestinal symptoms are the most commonly reported, and the overall safety profile is similar to tirzepatide and semaglutide.

Common gastrointestinal side effects (most prominent during the initial dosing period):

• Nausea (most commonly reported)
• Diarrhoea
• Vomiting
• Constipation

Rare but serious risks to monitor:

• Pancreatitis (as with other incretin-based therapies)
• Thyroid C-cell changes (flagged in preclinical data for the GLP-1 drug class)
• Gallbladder complications related to rapid weight loss
• Hypoglycemia risk when combined with other diabetes medications

No cases of severe hypoglycemia or drug-related fatalities were reported during Phase 2 trials.

FDA Approval Status and Availability

As of 2026, retatrutide is not yet FDA-approved and is not commercially available. It remains an investigational compound undergoing Phase 3 clinical evaluation. Approval is not expected before 2026 at the earliest.

Important: Any product sold as “retatrutide” through unregulated or black-market channels has not undergone the quality controls required for human administration. Always consult a qualified healthcare provider before using any weight loss peptide.

Comparing Retatrutide With Other Weight Loss Drugs

The clearest distinction lies in its mechanism. Wegovy (semaglutide) targets only GLP-1. Mounjaro (tirzepatide) adds GIP receptor agonism. Retatrutide adds a third layer with glucagon receptor activation, driving greater energy expenditure and fat breakdown.

Feature	Wegovy	Mounjaro	Retatrutide
GLP-1 Agonism	✓	✓	✓
GIP Agonism	No	✓	✓
Glucagon Agonism	No	No	✓
Avg. Weight Loss	~15%	~22.5%	~24.2%
Liver Fat Reduction	Modest	Moderate	Promising (early data)
FDA Approved	Yes	Yes	No (Phase 3)
Likely Clinical Niche	Obesity, T2D prevention	Obesity + T2D	Severe obesity, NAFLD, T2D

For a broader look at how receptor-targeting compounds are advancing across metabolic research, the ongoing medical research into SARMs offers relevant scientific context.

Practical Use: Dosing, Storage, and Administration

Retatrutide follows a stepwise dose-escalation schedule. Patients begin on a low starting dose and increase incrementally every four weeks. The highest dose evaluated in Phase 2 trials was 12 mg weekly.

1. Begin at the lowest prescribed dose (expected to be 2 mg weekly)
2. Increase incrementally under prescriber supervision every 4 weeks
3. Reach and maintain the target dose once tolerability is confirmed
4. Monitor weight, blood sugar levels, and metabolic markers throughout

Retatrutide should be stored refrigerated between 2°C and 8°C, away from direct light, and must not be frozen. For detailed guidance on handling peptide-based compounds, proper peptide storage is critical to maintaining potency and safety. Administer as a subcutaneous injection in the abdomen, thigh, or upper arm, rotating injection sites each week.

Losing Weight With Retatrutide

Clinical trial results are compelling, but medication alone is rarely the full picture for sustainable weight management. The best outcomes occur when retatrutide is combined with meaningful lifestyle changes, including nutritional improvements, increased physical activity, and consistent sleep habits.

Ongoing monitoring of body weight, blood sugar levels, and liver function is advisable throughout treatment. Patients and clinicians should plan for long-term weight maintenance from the outset rather than treating the medication as a short-term intervention.

Patient Guidance and Next Steps

If retatrutide’s clinical profile is relevant to your health situation, the most important first step is a consultation with a qualified healthcare provider. No weight loss medication should be started without a full clinical assessment covering existing conditions, other medications, and individual metabolic goals.

Stay informed through credible clinical sources as Phase 3 data continues to emerge. Regulatory updates will determine when and how retatrutide becomes available.

Frequently Asked Questions

What is retatrutide?

Retatrutide is a synthetic, long-acting weekly injectable peptide currently in Phase 3 clinical trials, classified as a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously.

How is retatrutide different from Ozempic?

Ozempic targets only the GLP-1 receptor. Retatrutide activates three receptors: GLP-1, GIP, and glucagon, providing broader metabolic coverage, greater energy expenditure, and stronger weight loss results in clinical trials.

How much weight can you lose on retatrutide?

In Phase 2 trials, participants lost an average of 17.5% of starting body weight at 24 weeks and 24.2% at 48 weeks on the highest dose. Individual results will vary based on dose, adherence, and lifestyle factors.

Is retatrutide approved for weight loss?

No. Retatrutide is not yet FDA-approved. It is undergoing Phase 3 clinical trials and approval is expected no earlier than 2026.

What are the most common side effects of retatrutide?

The most commonly reported side effects were gastrointestinal: nausea, diarrhoea, vomiting, and constipation. These were typically mild to moderate and most frequent during the initial dosing period.

Can retatrutide help with fatty liver disease?

Early data suggests retatrutide may significantly reduce liver fat in individuals with obesity and NAFLD. This is being investigated in Phase 3 trials. It is not yet licensed for NAFLD treatment.

 

Retatrutide is an investigational compound and is not yet approved for clinical use. This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any weight loss medication.